The diabetogenic action of statins — mechanisms and clinical implications (original) (raw)

• Endo, A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33, 1569–1582 (1992).
  CAS PubMed Google Scholar
• Goldstein, J. L. & Brown, M. S. The LDL receptor. Arterioscler. Thromb. Vasc. Biol. 29, 431–438 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Brown, M. S. & Goldstein, J. L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331–340 (1997).
  Article CAS PubMed Google Scholar
• Hunninghake, D. B. HMG-CoA reductase inhibitors. Curr. Opin. Lipidol. 3, 22–28 (1992).
  Article CAS Google Scholar
• Slater, E. E. & MacDonald, J. S. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative. Drugs 36 (Suppl. 3), 72–82 (1988).
  Article CAS PubMed Google Scholar
• [No authors listed] Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383–1389 (1994).
• Baigent, C. et al. Efficacy and safety of cholesterol-lowering treatment; prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 366, 1276–1278 (2005).
  Google Scholar
• Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371, 117–125 (2008).
• Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet 376, 1670–1681 (2010).
• Cholesterol Treatment Trialists' (CTT) Collaboration. The effects of lowering LDL-cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomized trials. Lancet 380, 581–590 (2012).
• Taylor, F. et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD004816. http://dx.doi.org/10.1002/14651858.CD004816.pub5.
• Armitage, J. The safety of statins in clinical practice. Lancet 370, 1781–1790 (2007).
  Article CAS PubMed Google Scholar
• Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195–2207 (2008).
  Article CAS PubMed Google Scholar
• FDA. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. FDA [online], (2012).
• Freeman, D. J. et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103, 357–362 (2001).
  Article CAS PubMed Google Scholar
• Coleman, C. I., Reinhart, K., Kluger, J. & White, C.M. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr. Med. Res. Opin. 24, 1359–1362 (2008).
  Article PubMed Google Scholar
• Sattar, N. et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375, 735–742 (2010).
  Article CAS PubMed Google Scholar
• Shepherd, J. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 360, 1623–1630 (2002).
  Article CAS PubMed Google Scholar
• Preiss, D. et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305, 2556–2564 (2011).
  Article CAS PubMed Google Scholar
• Waters, D. D. et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J. Am. Coll. Cardiol. 61, 148–152 (2013).
  Article CAS PubMed Google Scholar
• Rajpathak, S. N. et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 32, 1924–1929 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Dormuth, C. R. et al. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ 348, g3244 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Mora, S. et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 121, 1069–1077 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Chan, D. C. & Watts, G. F. Dyslipidemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert Opin. Pharmacother. 12, 13–30 (2011).
  Article CAS PubMed Google Scholar
• Culver, A. L. et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch. Intern. Med. 172, 144–152 (2012).
  Article PubMed Google Scholar
• Ruscica, M., Macchi, C., Morlotti, B., Sirtori, C.R. & Magni, P. Statin therapy and related risk of new-onset type 2 diabetes mellitus. Eur. J. Intern. Med. 25, 401–406 (2014).
  Article CAS PubMed Google Scholar
• Sattar, N. A. et al. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atheroscler. Suppl. 15, 1–15 (2014).
  Article PubMed Google Scholar
• Sekhar, M. S. & Unnikrishnan, M. K. South-Asian population has a higher likelihood for diabetes risk for statins regardless of potency. Med. Hypotheses 84, 283–284 (2015).
  Article CAS Google Scholar
• Waters, D. D. et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized trials. J. Am. Coll. Cardiol. 57, 1535–1545 (2011).
  Article CAS PubMed Google Scholar
• Ridker, P. M. et al. Cardiovascular benefits and diabetes risk of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380, 565–571 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Arnaboldi, L. & Corsini, A. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atheroscler. Suppl. 16, 1–27 (2015).
  Article PubMed Google Scholar
• Chan, D. C., Pang, J. & Watts, G. F. Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10. Curr. Atheroscler. Rep. 17, 472 (2015).
  Article CAS PubMed Google Scholar
• Sabatine, M. S. et al. High-dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 sub study [abstract]. Circulation 110, S834 (2004).
  Google Scholar
• Sasaki, J., Iwashita, M. & Kono, M. Statins: beneficial or adverse for glucose metabolism. J. Atheroscler. Thromb. 13, 123–129 (2006).
  Article CAS PubMed Google Scholar
• Chapman, M. J. et al. Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPTAIN and PREVAIL-US studies. Curr. Med. Res. Opin. 30, 775–784 (2014).
  Article CAS PubMed Google Scholar
• Cederberg, H. et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 58, 1109–1117 (2015).
  Article CAS PubMed Google Scholar
• Yamakawa, T. et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J. Atheroscler. Thromb. 15, 269–275 (2008).
  Article CAS PubMed Google Scholar
• Teramoto, T. et al. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin. Pharmacother. 11, 817–828 (2010).
  Article CAS PubMed Google Scholar
• Odawara, M. et al. Pitavastatin for the delay or prevention of diabetes development in individuals with impaired glucose tolerance. American Diabetes Association [online], (2013).
  Google Scholar
• Cho, Y. et al. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors. Metabolism 64, 482–488 (2015).
  Article CAS PubMed Google Scholar
• Vallejo-Vaz, A. J. et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: a meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis 241, 409–418 (2015).
  Article CAS PubMed Google Scholar
• Erqou, S., Lee, C. C. & Adler, A. I. Statins and glycemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia 57, 2444–2452 (2014).
  Article CAS PubMed Google Scholar
• Ray, K. K. et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials. Lancet 373, 1765–1772 (2009).
  Article CAS PubMed Google Scholar
• Colhoun, H. M. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet 364, 685–696 (2004).
  Article CAS PubMed Google Scholar
• Swerdlow, D. I. & Sattar, N. A dysglycaemic effect of statins in diabetes: relevance to clinical practice? Diabetologia 57, 2433–2435 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• van de Woestijne, A. P., van der Graaf, Y., Westerink, J., Nathoe, H. M. & Visseren, F. L. Effect of statin therapy on incident type 2 diabetes mellitus in patients with clinically manifest vascular disease. Am. J. Cardiol. 115, 441–446 (2015).
  Article CAS PubMed Google Scholar
• Skoumas, J. et al. Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia. Atherosclerosis 237, 140–145 (2014).
  Article CAS PubMed Google Scholar
• Panz, V., Immelman, A., Paiker, J., Pilcher, G. & Raal, F. High-dose statin therapy does not induce insulin resistance in patients with familial hypercholesterolemia. Metab. Syndr. Relat. Disord. 10, 351–357 (2012).
  Article CAS PubMed Google Scholar
• Besseling, J., Kastelein, J. J., Defesche, J. C., Hutton, B. A. & Hovingh, G. K. Association between familial hypercholesterolaemia and prevalence of type 2 diabetes mellitus. JAMA 313, 1029–1036 (2015).
  Article CAS PubMed Google Scholar
• Swerdlow, D. J. et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 385, 351–361 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Czech, M. P. Cellular basis of insulin insensitivity in large rat adipocytes. J. Clin. Invest. 57, 1523–1532 (1976).
  Article PubMed PubMed Central CAS Google Scholar
• Olefsky, J. M. Mechanisms of decreased insulin responsiveness of large adipocytes. Endocrinology 100, 1169–1177 (1977).
  Article CAS PubMed Google Scholar
• Friedman, J. M. Obesity in the new millennium. Nature 404, 632–634 (2000).
  Article CAS PubMed Google Scholar
• Kovanen, P. T., Nikkila, E. A. & Miettinen, T. A. Regulation of cholesterol synthesis and storage in fat cells. J. Lipid Res. 16, 211–223 (1975).
  CAS PubMed Google Scholar
• Krause, B. R. & Hartman, A. D. Adipose tissue and cholesterol metabolism. J. Lipid Res. 25, 97–110 (1984).
  CAS PubMed Google Scholar
• Van Harmelen, V. et al. Increased adipose angiotensinogen gene expression in human obesity. Obes. Res. 8, 337–341 (2000).
  Article CAS PubMed Google Scholar
• Hotamisligil, G. S., Shargill, N. S. & Spiegelman, B. M. Adipose expression of tumour necrosis factor-α: a direct role in obesity-linked insulin resistance. Science 259, 87–91 (1993).
  Article CAS PubMed Google Scholar
• Fried, S. K., Bunkin, D. A. & Greenberg, S. A. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6, depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 83, 847–850 (1998).
  CAS PubMed Google Scholar
• Le Lay, S. et al. Cholesterol, a cell size-dependent signal that regulates glucose metabolism and gene expression in adipocytes. J. Biol. Chem. 276, 16904–16910 (2001).
  Article CAS PubMed Google Scholar
• Parpal, S., Karlsson, M., Thorn, H. & Strålfors, P. Cholesterol depletion disrupts caveolae and insulin receptor signalling for metabolic control via insulin receptor substrate-1 but not for mitogen-activated protein kinase control. J. Biol. Chem. 276, 9670–9678 (2001).
  Article CAS PubMed Google Scholar
• Gustavasson, J. et al. Localization of the insulin receptor in caveolae of adipocyte plasma membrane. FASEB J. 13, 1961–1971 (1999).
  Article Google Scholar
• Chamberlain, L. H. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett. 507, 357–361 (2001).
  Article CAS PubMed Google Scholar
• Takaguri, A., Sotoh, K., Itagaki, M., Tokumitsu, Y. & Ichihara, K. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L-1 adipocytes. J. Pharmacol. Sci. 107, 80–89 (2008).
  Article CAS PubMed Google Scholar
• Ganesan, S. & Ito, M. K. Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-L1 adipocytes. Metab. Syndr. Relat. Disord. 11, 251–255 (2013).
  Article CAS PubMed Google Scholar
• Donath, M. Y. & Shoelson, S. E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11, 98–107 (2011).
  Article CAS PubMed Google Scholar
• Shoelson, S. E., Lee, J. & Goldfine, A. B. Inflammation and insulin resistance. J. Clin. Invest. 116, 1793–1801 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• Jager, J., Grémeaux, T., Cormont, M., Le Marchand-Brustel, Y. & Tanti, J. F. Interleukin-β-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 148, 241–251 (2007).
  Article CAS PubMed Google Scholar
• Lagathu, C. Long term treatment with interleukin-1β induces insulin resistance in murine and human adipocytes. Diabetologia 49, 2162–2173 (2006).
  Article CAS PubMed Google Scholar
• Vandanmagsar, B. et al. The NLRP3 inflammasone instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179–188 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• Stienstra, R. et al. The inflammasone-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 12, 593–605 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Lee H-M. et al. Upregulated NLRP3 inflammasome in patients with type 2 diabetes. Diabetes 62, 194–204 (2013).
  Article CAS PubMed Google Scholar
• Henriskbo, B. D. et al. Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. Diabetes 63, 3742–3747 (2014).
  Article CAS Google Scholar
• Baker, W. L., Talati, R., White, C. M. & Coleman, C. I. Differing effects on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res. Clin. Pract. 87, 98–107 (2010).
  Article CAS PubMed Google Scholar
• Kadowaki, T. et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes and the metabolic syndrome. J. Clin. Invest. 116, 1784–1792 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• Li, S., Shin, H. J., Ding, E. L. & van Dam, R. M. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302, 179–188 (2009).
  Article CAS PubMed Google Scholar
• Hara, K. et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 51, 536–540 (2002).
  Article CAS PubMed Google Scholar
• Kondo, H. et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 51, 2325–2328 (2002).
  Article CAS PubMed Google Scholar
• Strumvoll, M. et al. Association of the T-G polymorphism in adiponectin (exon 20 with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes 51, 37–41 (2002).
  Article Google Scholar
• Roehrich, M. E. et al. Insulin-secreting β-cell dysfunction induced by human lipoproteins. J. Biol. Chem. 278, 18368–18375 (2003).
  Article CAS PubMed Google Scholar
• Hao, M., Head, W. S., Gunawardeana, S. C., Hasty, A. H. & Piston, D. W. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic β-cell dysfunction. Diabetes 56, 2328–2338 (2007).
  Article CAS PubMed Google Scholar
• Rütti, S. et al. Low and high density lipoproteins modulate function, apoptosis and proliferation of primary human and murine pancreatic β-cells. Endocrinology 150, 4521–4530 (2009).
  Article CAS PubMed Google Scholar
• Kruit, J. K., Brunham, L. R., Verchere, C. B. & Hayden, M. R. HDL and LDL cholesterol significantly influence β-cell function in type 2 diabetes mellitus. Curr. Opin. Lipidol. 21, 178–185 (2010).
  Article CAS PubMed Google Scholar
• Brunham, L. R. et al. β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat. Med. 13, 340–347 (2007).
  CAS PubMed Google Scholar
• Fryirs, M. A. et al. Effects of high-density lipoproteins on pancreatic β-cell insulin secretion. Arterioscler. Thromb. Vasc. Biol. 30, 1642–1648 (2010).
  Article CAS PubMed Google Scholar
• Sturek, J. M. et al. An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic β cells. J. Clin. Invest. 120, 2575–2589 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Bogan, J. S., Xu, Y. & Hao, M. Cholesterol accumulation increases insulin granule size and impairs membrane trafficking. Traffic 13, 1466–1480 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Metz, S. A., Rabaglia, M. E., Stock, J. B. & Kowluru, A. Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP-binding proteins. Biochem. J. 295, 31–40 (1993).
  Article PubMed PubMed Central CAS Google Scholar
• Li, G., Regazzi, R., Roche, E. & Wollheim, C. B. Blockade of mevalonate production by lovastatin attenuates bombesin and vasopressin potentiation of nutrient-induced insulin secretion in HIT-T15 cells. Biochem. J. 289, 379–385 (1993).
  Article PubMed PubMed Central CAS Google Scholar
• Yada, T., Nakata, M., Shiraishi, T. & Kakei, M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet β-cells. Br. J. Pharmacol. 126, 1205–1213 (1999).
  Article PubMed PubMed Central CAS Google Scholar
• Zhou, J. et al. Effect of glucose metabolism in mouse MIN6 cells. J. Diabetes Res. 2014, 376570 (2014).
  PubMed PubMed Central Google Scholar
• Chen, Z. et al. Atorvastatin helps preserve pancreatic β cell function in obese C57BL/6 J mice and the effect is related to increased pancreas proliferation and amelioration of endoplasmic-reticulum stress. Lipids Health Dis. 13, 98 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Mita, T. et al. Preferable effect of pravastatin compared to atorvastatin on β cell function in Japanese early-state type 2 diabetes with hypercholesterolemia. Endocr. J. 54, 441–447 (2007).
  Article CAS PubMed Google Scholar
• Stumvoll, M. et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23, 295–301 (2000).
  Article CAS PubMed Google Scholar
• Matsuda, M. & DeFronzo, R. A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycaemic insulin clamp. Diabetes Care 22, 1462–1470 (1999).
  Article CAS PubMed Google Scholar
• Larsen, S. et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. JAMA 61, 44–53 (2013).
  CAS Google Scholar
• Banach, M. et al. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr. Pharm. Des. 19, 4904–4912 (2013).
  Article CAS PubMed Google Scholar
• Barylski, M. et al. Statins and new-onset diabetes. Curr. Pharm. Des. 20, 3657–3664 (2014).
  Article CAS PubMed Google Scholar
• Sattar, N. & Taskinen, M. R. Statins are diabetogenic—myth or reality? Atheroscler. Suppl. 13, 1–10 (2012).
  Article CAS PubMed Google Scholar
• Lindström, J. et al. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3 year results on diet and physical activity. Diabetes Care 26, 3230–3236 (2003).
  Article PubMed Google Scholar
• Lindström, J. et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368, 1673–1679 (2006).
  Article PubMed Google Scholar
• Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002).
  Article CAS PubMed Google Scholar
• Diabetes Prevention Program Research Group. The 10 year cost-effectiveness of lifestyle and metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 35, 723–730 (2012).
• Fradkin, J. E., Roberts, B. T. & Rodgers, G. P. What's preventing us from preventing type 2 diabetes? N. Engl. J. Med. 367, 1177–1179 (2012).
  Article CAS PubMed Google Scholar
• Nielsen, S. F. & Nordestgaard, B. G. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Lancet Diabetes Endocrinol. 2, 894–900 (2014).
  Article CAS PubMed Google Scholar
• Chen, S. C & Tseng, C. H. Dyslipidaemia, kidney disease and cardiovascular disease in diabetic patients. Rev. Diabet. Stud. 10, 88–100 (2013).
  Article PubMed PubMed Central Google Scholar
• Zafrir, B. & Jain, M. Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications. Cardiovasc. Drugs Ther. 28, 361–377 (2014).
  Article CAS PubMed Google Scholar
• Tennebaum, A. & Fisman, E. Z. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc. Diabetol. 11, 140–149 (2012).
  Article CAS Google Scholar